EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Development of nanomedicines for the treatment of Alzheimer’s disease: Raison d’être, strategies, challenges and regulatory aspects

Farhan Mazahir, Md Imtiyaz Alam, Awesh Kumar Yadav

Ageing Research Reviews · 2024-07 · 98 · 102318

DOI: 10.1016/j.arr.2024.102318 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2024-07. Verfasst von Farhan Mazahir und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Raebareli, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Nanomedicine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 369 Literaturangaben. Gefördert von: Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India, National Institute of Pharmaceutical Education and Research Raebareli.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a chronic neurodegenerative disorder characterized by progressive loss of memory. Presently, AD is challenging to treat with current drug therapy as their delivery to the brain is restricted by the presence of the blood-brain barrier. Nanomedicines, due to their size, high surface volume ratio, and ease of tailoring drug release characteristics, showed their potential to treat AD. The nanotechnology-based formulations for brain targeting are expected to enter the market in the near future. So, regulatory frameworks are required to ensure the quality, safety, and effectiveness of the nanomedicines to treat AD. In this review, we discuss different strategies, in-vitro blood-brain permeation models, in-vivo permeation assessment, and regulatory aspects for the development of nanomedicine to treat AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseNanomedicineHumansAnimalsBlood-Brain BarrierDrug Delivery Systems

Stichwörter der Autor:innen

Alzheimer’s diseaseAmyloid-βBlood-Brain BarrierBrain permeabilityHyperphosphorylated Tau proteinNanocarriers

Autor:innen und Institutionen

  • Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Raebareli, India.
  • Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Raebareli, India. Electronic address: awesh.yadav@niperraebareli.edu.in.

Förderung

  • Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India
  • National Institute of Pharmaceutical Education and Research Raebareli

Zitieren

APA

Mazahir, F., Alam, M. I., & Yadav, A. K. (2024). Development of nanomedicines for the treatment of Alzheimer’s disease: Raison d’être, strategies, challenges and regulatory aspects. Ageing Research Reviews, 98, 102318. https://doi.org/10.1016/j.arr.2024.102318

Vancouver

Mazahir F, Alam MI, Yadav AK. Development of nanomedicines for the treatment of Alzheimer’s disease: Raison d’être, strategies, challenges and regulatory aspects. Ageing Research Reviews. 2024;98:102318. doi:10.1016/j.arr.2024.102318

BibTeX
@article{Mazahir2024,
  author = {Mazahir, Farhan and Alam, Md Imtiyaz and Yadav, Awesh Kumar},
  title = {Development of nanomedicines for the treatment of Alzheimer’s disease: Raison d’être, strategies, challenges and regulatory aspects},
  journal = {Ageing Research Reviews},
  year = {2024},
  volume = {98},
  pages = {102318},
  doi = {10.1016/j.arr.2024.102318}
}
Kostenlos starten →